Therapy News and Research

RSS

New report evaluating use of SBRT in lung cancer treatment released

The American Society for Radiation Oncology has released its Emerging Technology Committee's report evaluating the use of stereotactic body radiotherapy in lung cancer treatment.

29 Apr 2010

Elderly and whites seek alternative therapies for pain relief: Study

In a University of Michigan Health System study, 1 out of 3 patients with chronic pain reported using complementary and alternative medicine therapies such as acupuncture and chiropractic visits for pain relief.

29 Apr 2010

Higher the blood cholesterol level, greater the risk of atherosclerosis: Study

In addition to crystallized cholesterol, atherosclerotic plaques always contain large quantities of immune cells but, surprisingly, no bacteria or viruses. It was previously unclear just how the body's own defence forces are called into action. Even animals that are kept in an absolutely sterile environment can suffer from "clogging" or "furring" of the arteries when their food contains high levels of cholesterol.

29 Apr 2010

Experts discuss recent advancements in personalized medicine for treating childhood disorders

Many of the world's leading experts in pediatric pharmacogenomics and personalized medicine are gathering today at a first-of-its-kind conference in Kansas City to change the way childhood diseases and illnesses are treated.

29 Apr 2010

Study examines lifestyle-related causes of death in AIDS patients

The study, by researchers from the University of Bristol and a large group of international collaborators, examined data from the Antiretroviral Therapy Cohort Collaboration (ART-CC) which involved nearly 40,000 patients who started ART between 1996 and 2006 in Europe and North America.

29 Apr 2010

MU researcher develops test to pinpoint neurological origins of dysphagia

Muscle degeneration and confinement to a wheelchair are the hallmarks of Lou Gehrig's disease, Parkinson's, muscular dystrophy and other neurodegenerative diseases. One of the silent, and most serious, symptoms of these diseases is losing the ability to swallow.

29 Apr 2010

ATIR shows better clinical results in patients receiving mismatched bone marrow transplantation

Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants.

29 Apr 2010

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Combination antibiotics effectively treat Chlamydia-induced reactive arthritis - a major step toward management, and possibly cure, of this disease, a federal multicenter clinical trial led by the University of South Florida College of Medicine found.

29 Apr 2010

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemotherapy and radiotherapy. Researchers writing in BioMed Central's open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect.

29 Apr 2010

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three months ended March 31, 2010, and filed its first quarter 2010 Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Apr 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.

29 Apr 2010

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

Xlumena receives FDA clearance to market NAVIX Access Device

Xlumena, a privately held provider of innovative technology for gastroenterologists/interventional endoscopists, today announced it has received clearance from the US Food and Drug Administration to market its NAVIX Access Device.

28 Apr 2010

Celera reports net loss of $12.5M for first-quarter 2010

Celera Corporation today reported net revenues of $31.4 million for the first quarter of 2010 that ended March 27, 2010, compared to $45.7 million in the prior year quarter. For the first quarter of 2010, Celera reported a net loss $12.5 million, or $0.15 per share, compared to a net loss of $1.4 million, or $0.02 per share, for the prior year quarter.

28 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month.

28 Apr 2010

Therapy News and Research

New report evaluating use of SBRT in lung cancer treatment released

Elderly and whites seek alternative therapies for pain relief: Study

Higher the blood cholesterol level, greater the risk of atherosclerosis: Study

Experts discuss recent advancements in personalized medicine for treating childhood disorders

Study examines lifestyle-related causes of death in AIDS patients

MU researcher develops test to pinpoint neurological origins of dysphagia

ATIR shows better clinical results in patients receiving mismatched bone marrow transplantation

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Study calls for optimized medical treatment for older patients with advanced lung cancer

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Investigators study Pioglitazone and Vitamin E for treatment of NASH

Xlumena receives FDA clearance to market NAVIX Access Device

Celera reports net loss of $12.5M for first-quarter 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News